top of page

Dr. Calley Hirsch, Leader in Preclinical Translation, Joins Morphocell Technologies as Vice President of Preclinical Development


Montreal, QC, January 17, 2024 – Morphocell Technologies is thrilled to announce the appointment of Dr. Calley Hirsch as our new Vice President of Preclinical Development


With over 18 years of international experience, Dr. Hirsch is a renowned specialist in cell and gene therapy development. Her expertise, built on a solid training foundation in cellular reprogramming and stem cell biology, has been instrumental in advancing numerous stem cell-derived and primary cell therapies to the clinic. Her previous roles at CCRM, BlueRock Therapeutics, and Artisan Bio have established her as an expert in translating cell therapy product concepts into clinical products.

Dr. Claudia Raggi, Chief Technology Officer, expressed her enthusiasm for Calley's addition to the team: "Calley's exceptional skill set and dedication to innovation in cell and gene therapy are aligned perfectly with Morphocell's vision. Her leadership in preclinical translation will be invaluable as we continue to develop groundbreaking products and strategies to revolutionize the treatment of liver disease."

Calley shared her enthusiasm: "Joining Morphocell Technologies is a unique opportunity to contribute to a company that's at the forefront of cell therapy innovation. I am eager to apply my experience in preclinical development to help bring transformative therapies to patients. This role represents a significant step in my career, and I am committed to ensuring that our groundbreaking research translates into real-world solutions."

Calley's commitment to developing next-generation products and her passion for streamlining product access to the clinic and beyond make her an ideal fit for this role, and we are excited to see the impact she will have at Morphocell Technologies.

About Morphocell Technologies Inc.

Morphocell Technologies is a Montreal-based regenerative medicine company focused on the development and commercialization of stem cell-derived tissue and organ replacement therapies. Its iPSC-derived platform technology has a large pipeline potential touching different organ deficiencies, with severe liver disease being the initial focus. Morphocell prides itself on its culture of innovation, technical excellence, and commitment to improving patients' lives. 


Media Contact:

Zaynah Ibrahim

+ 1 (514) 373-6444 ext. 106

bottom of page